Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab in advanced solid tumors
NCT02492789Phase 1Completed
- Sponsor
- Atridia Pty Ltd
- Start
- Sep 2015
- Primary completion
- Mar 2019
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camrelizumab in solid tumor, endometrial carcinoma, thymic carcinoma (TC) and 2 more, sponsored by Atridia Pty Ltd. Primary endpoint: Number of Participants with Adverse Events as a Measure of Safety and Tolerability at 15 months. Started Sep 2015; status: completed.
02
Drugs
camrelizumab
03
Conditions
solid tumorendometrial carcinomathymic carcinoma (TC)biliary tract carcinoma (BTC)carcinoma of unknown primary (CUP)
Beyond the preview
Go deeper on NCT02492789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02492789.